如何治疗适合移植的骨髓纤维化患者
尽管JAK抑制剂和新药获批,骨髓纤维化(MF)的疾病修饰反应仍有限,造血干细胞移植(HSCT)是唯一可能治愈的手段。本文通过3个临床场景阐述HSCT适应证决策、按风险分层实施移植、减少移植相关并发症及利用移植物抗MF效应的最新方法。
要点
- HSCT仍是MF唯一可能治愈的治疗选择,但治疗相关并发症和死亡率限制其应用。
- MF患者常年龄较大,伴血细胞减少、脾大和严重骨髓纤维化,移植全程管理面临挑战。
- 分子分析改善了对疾病机制的理解并推动新药研发,但移植场景的前瞻性试验常缺乏。
核心结论
- HSCT是MF唯一可能治愈的治疗选择,但治疗相关并发症和死亡率限制其应用。
- 分子分析改善了对疾病机制的理解并推动新药研发,但移植场景的前瞻性试验常缺乏,使循证决策尤为困难。
研究设计与样本
- 本文为「如何治疗」类综述,通过3个不同临床场景阐述MF患者HSCT的决策与实施。
主要发现
- 尽管JAK抑制剂和新药获批,MF的疾病修饰反应仍有限。
- 全球范围内MF的HSCT数量持续增加。
- MF患者常年龄较大,伴血细胞减少、脾大和严重骨髓纤维化,移植全程管理存在挑战。
临床怎么用
- 本文通过3个临床场景展示影响HSCT适应证决策的相关方面。
- 本文描述按不同风险类别实施HSCT的方法。
- 本文讨论减少移植相关并发症的最新方法。
- 本文展示如何利用移植物抗MF效应,尤其在移植后阶段以取得最佳结局。
局限性
- 移植场景的前瞻性试验常缺乏,使循证决策尤为困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the approval of Janus kinase inhibitors and novel agents for patients with myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment option. The number of HSCTs for MF continues to increase worldwide, but its inherent therapy-related morbidity and mortality limit its use for many patients. Furthermore, patients with MF often present at an older age, with cytopenia, splenomegaly, and severe bone marrow fibrosis, posing challenges in managing them throughout the HSCT procedure. Although implementation of molecular analyses enabled improved understanding of disease mechanisms and subsequently sparked development of novel drugs with promising activity, prospective trials in the HSCT setting are often lacking, making an evidence-based decision process particularly difficult. To illustrate how we approach patients with MF with respect to HSCT, we present 3 different clinical scenarios to capture relevant aspects that influence our decision making regarding indication for, or against, HSCT. We describe how we perform HSCT according to different risk categories and, furthermore, discuss our up-to-date approach to reduce transplant-related complications. Last, we show how to harness graft-versus-MF effects, particularly in the posttransplant period to achieve the best possible outcomes for patients.
引用
- Kröger N, Wolschke C, Gagelmann N, et al. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023. PMID: 37647853. doi:10.1182/blood.2023021218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。